Group One Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Group One Trading’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.6K	Buy	+1,998	New	+$17.4K	﹤0.01%	6011
2025 Q1	–	Sell	-3,711	Closed	-$17.5K	–	7824
2024 Q4	$20.7K	Buy	+3,711	New	+$29.1K	﹤0.01%	5661
2024 Q3	–	Sell	-2,065	Closed	-$34.3K	–	6825
2024 Q2	$43.3K	Buy	+2,065	New	+$51.8K	﹤0.01%	4620
2024 Q1	–	Sell	-3,691	Closed	-$94.2K	–	7297
2023 Q4	$74.8K	Buy	3,691 +3,266	+768%	+$43K	﹤0.01%	4717
2023 Q3	$5.41K	Sell	425 -616	-59%	-$10.3K	﹤0.01%	6662
2023 Q2	$18.8K	Buy	1,041 +250	+32%	+$4.6K	﹤0.01%	6027
2023 Q1	$13.6K	Buy	+791	New	+$15.4K	﹤0.01%	5766
2022 Q1	–	Sell	-242	Closed	-$5K	–	8220
2021 Q4	$5K	Buy	+242	New	+$5.93K	﹤0.01%	7629

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Group One Trading's FDMT Position: Q1 2026 in Review

Group One Trading opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 1,998 shares worth $18.6K. The stake represents ﹤0.01% of the portfolio and ranks #6011 among its holdings. This is a return to the name: Group One Trading previously reported a position in FDMT as recently as Q4 2024.

Group One Trading first reported a position in FDMT in Q4 2021 and has held it in 8 quarters since. The position peaked at $74.8K in Q4 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Group One Trading held 1,998 shares of 4D Molecular Therapeutics worth $18.6K as of Q1 2026.
4D Molecular Therapeutics was a new Group One Trading position in Q1 2026.
4D Molecular Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6011 holding.
Group One Trading first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 8 quarters since.
Group One Trading's 4D Molecular Therapeutics position peaked at $74.8K in Q4 2023.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.